The Eukaryotic Translation Initiation Factor 4GI Is Cleaved by Different Retroviral Proteases

Journal of Virology

Volumn 77, Issue 23, 2003, Pages 12392-12400

  Álvarez, Enrique ^a   Menéndez Arias, Luis ^a   Carrasco, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4G; INITIATION FACTOR 4GI; RETROVIRUS PROTEASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CELL TRANSFER; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME SUBSTRATE; EUKARYOTE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS 1; HYDROLYSIS; INTERNAL RIBOSOME ENTRY SITE; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; PROTEINASE INHIBITION; REGULATORY MECHANISM; RETROVIRUS; RNA ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSLATION INITIATION;

ANIMALS; BASE SEQUENCE; COS CELLS; DNA PRIMERS; ENDOPEPTIDASES; EUKARYOTIC INITIATION FACTOR-4G; HYDROLYSIS; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0242661870     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.23.12392-12400.2003     Document Type: Article

References (57)

1. Agy, M. B., M. Wambach, K. Foy, and M. G. Katze. 1990. Expression of cellular genes in CD4 positive lymphoid cells infected by the human immunodeficiency virus, HIV-1: evidence for a host protein synthesis shut-off induced by cellular mRNA degradation. Virology 177:251-258.
2. Aldabe, R., E. Feduchi, I. Novoa, and L. Carrasco. 1995. Efficient cleavage of p220 by poliovirus 2Apro expression in mammalian cells: effects on vaccinia virus. Biochem. Biophys. Res. Commun. 215:928-936.
3. Attal, J., M. C. Theron, F. Taboit, M. Cajero-Juarez, G. Kann, P. Bolifraud, and L. M. Houdebine. 1996. The RU5 ('R') region from human leukaemia viruses (HTLV-1) contains an internal ribosome entry site (IRES)-like sequence. FEBS Lett. 392:220-224.
4. Baudin, F., R. Marquet, C. Isel, J. L. Darlix, B. Ehresmann, and C. Ehresmann. 1993. Functional sites in the 5′ region of human immunodeficiency virus type 1 RNA form defined structural domains. J. Mol. Biol. 229:382-397.
5. Berlioz, C., and J.-L. Darlix. 1995. An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors. J. Virol. 69:2214-2222.
6. Berlioz, C., C. Torrent, and J.-L. Darlix. 1995. An internal ribosomal entry signal in the rat VL30 region of the Harvey murine sarcoma virus leader and its use in dicistronic retroviral vectors. J. Virol. 69:6400-6407.
7. 2/M phase of the cell cycle. J. Virol. 77:3939-3949.
8. Buck C. B., X. Shen, M. A. Egan, T. C. Pierson, C. M. Walker, and R. F. Siliciano. 2001. The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J. Virol. 75:181-191.
9. Byrd, M. P., M. Zamora, and R. E. Lloyd. 2002. Generation of multiple isoforms of eukaryotic translation initiation factor 4GI by use of alternate translation initiation codons. Mol. Cell. Biol. 22:4499-4511.
10. Deffaud, C., and J.-L. Darlix. 2000. Characterization of an internal ribosomal entry segment in the 5′ leader of murine leukemia virus env RNA. J. Virol. 74:846-850.
11. Deffaud, C., and J.-L. Darlix. 2000. Rous sarcoma virus translation revisited: characterization of an internal ribosome entry segment in the 5′ leader of the genomic RNA. J. Virol. 74:11581-11588.
12. De Gregorio, E., T. Preiss, and M. W. Hentze. 1998. Translational activation of uncapped mRNAs by the central part of human eIF4G is 5′ end-dependent. RNA 4:828-836.
13. Dunn, B. M. 1998. Human immunodeficiency virus 1 retropepsin, p. 919-928. In A. J. Barret, N. D. Rawlings, and J. F. Woessner (ed.), Handbook of proteolytic enzymes. Academic Press, London, United Kingdom.
14. Elroy-Stein, O., T. R. Fuerst, and B. Moss. 1989, Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5′ sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. USA 86:6126-6130.
15. Fukunaga, R., and T. Hunter. 1997. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16:1921-1933.
16. Goh, W. C., M. E. Rogel, C. M. Kinsey, S. F. Michael, P. N. Fultz, M. A. Nowak, B. H. Hahn, and M. Emerman. 1998. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71.
17. Gradi, A., H. Imataka, Y. V. Svitkin, E. Rom, B. Raught, S. Morino, and N. Sonenberg. 1998. A novel functional human eukaryotic translation initiation factor 4G. Mol. Cell. Biol. 18:334-342.
18. Hentze, M. W. 1997. eIF4G: a multipurpose ribosome adapter? Science 275:500-501.
19. Imataka, H., A. Gradi, and N. Sonenberg. 1998. A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation. EMBO J. 17:7480-7489.
20. Imataka, H., H. S. Olsen, and N. Sonenberg. 1997. A new translational regulator with homology to eukaryotic translation initiation factor 4G. EMBO J. 16:817-825.
21. Imataka, H., and N. Sonenberg. 1997. Human eukaryotic translation initiation factor 4G (eIF4G) possesses two separate and independent binding sites for eIF4A. Mol. Cell. Biol. 17:6940-6947.
22. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, N. E. Wideburg, A. Saldivar, R. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
23. Kirchweger, R., E. Ziegler, B. J. Lamphear, D. Waters, H.-D. Liebig, W. Sommergruber, F. Sobrino, C. Hohenadl, D. Blaas, R. E. Rhoads, and T. Skern. 1994. Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4γ. J. Virol. 68:5677-5684.
24. Kobayashi, M., Y. Ohi, T. Asano, T. Hayakawa, K. Kato, A. Kakinuma, and M. Hatanaka. 1991. Purification and characterization of human T-cell leukemia virus type I protease produced in Escherichia coli. FEBS Lett. 293:106-110.
25. Kornfeld, H., N. Riedel, G. A. Viglianti, V. Hirsch, and J. I. Mullins. 1987. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature 326:610-613.
26. Lamphear, B. J., R. Kirchweger, T. Skern, and R. E. Rhoads. 1995. Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. J. Biol. Chem. 270:21975-21983.
27. Lopez-Lastra, M., C. Gabus, and J. L. Darlix. 1997. Characterization of an internal ribosomal entry segment within the 5′ leader of avian reticuloendotheliosis virus type A RNA and development of novel MLV-REV-based retroviral vectors. Hum. Gene Ther. 8:1855-1865.
28. Luftig, R. B., and L. D. Lupo. 1994. Viral interactions with the host-cell cytoskeleton: the role of retroviral proteases. Trends Microbiol. 2:178-182.
29. Menéndez-Arias, L., D. Gotte, and S. Oroszlan. 1993. Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 196:557-563.
30. Menéndez-Arias, L., I. T. Weber, and S. Oroszlan. 1995. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases. J. Biol. Chem. 270:29162-29168.
31. Menéndez-Arias, L., I. T. Weber, J. Soss, R. W. Harrison, D. Gotte, and S. Oroszlan. 1994. Kinetic and modeling studies of subsites S4-S3′ of Moloney murine leukemia virus protease. J. Biol. Chem. 269:16795-16801.
32. Menéndez-Arias, L., M. Young, and S. Oroszlan. 1992. Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J. Biol. Chem. 267:24134-24139.
33. Morino, S., H. Imataka, Y. V. Svitkin, T. V. Pestova, and N. Sonenberg. 2000. Eukaryotic translation initiation factor 4E (eIF4E) binding site and the middle one-third of eIF4GI constitute the core domain for cap-dependent translation, and the C-terminal one-third functions as a modulatory region. Mol. Cell. Biol. 20:468-477.
34. Morley, S. J., P. S. Curtis, and V. M. Pain. 1997. eIF4G: translation's mystery factor begins to yield its secrets. RNA 3:1085-1104.
35. Ohlmann, T., M. Lopez-Lastra, and J. L. Darlix. 2000. An internal ribosome entry segment promotes translation of the simian immunodeficiency virus genomic RNA. J. Biol. Chem. 275:11899-11906.
36. Ohlmann, T., D. Prevot, D. Decimo, F. Roux, J. Garin, S. J. Morley, and J. L. Darlix. 2002. In vitro cleavage of eIF4GI but not eF4GII by HIV-1 protease and its effects on translation in the rabbit reticulocyte lysate system. J. Mol. Biol. 318:9-20.
37. Prevot, D., D. Decimo, C. H. Herbreteau, F. Roux, J. Garin, J. L. Darlix, and T. Ohlmann. 2003. Characterization of a novel RNA-binding region of eIF4GI critical for ribosomal scanning. EMBO J. 22:1909-1921.
38. Pyronnet, S., H. Imataka, A. C. Gingras, R. Fukunaga, T. Hunter, and N. Sonenberg. 1999. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 18:270-279.
39. Rittenhouse, J., M. C. Turon, R. J. Helfrich, K. S. Albrecht, D. Weigl, R. L. Simmer, F. Mordini, J. Erickson, and W. E. Kohlbrenner. 1990. Affinity, purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. Biochem. Biophys. Res. Commun. 171:60-66.
40. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
41. Shoeman, R. L., B. Honer, T. J. Stoller, C. Kesselmeier, M. C. Miedel, P. Traub, and M. C. Graves. 1990. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. USA 87:6336-6340.
42. Somasundaran, M., and H. L. Robinson. 1988. Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. Science 242:1554-1557.
43. Tomasselli, A. G., and R. L. Heinrikson. 1994. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:279-301.
44. Tomasselli, A. G., J. O. Hui, L. Adams, J. Chosay, D. Lowery, B. Greenberg, A. Yem, M. R. Deibel, H. Zurcher-Neely, and R. L. Heinrikson. 1991. Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. J. Biol. Chem. 266:14548-14553.
45. Tomasselli, A. G., J. O. Hui, T. K. Sawyer, D. J. Staples, C. Bannow, I. M. Reardon, W. J. Howe, D. L. DeCamp, C. S. Craik, and R. L. Heinrikson. 1990. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J. Biol. Chem. 265:14675-14683.
46. Tözsér, J., I. Blaha, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
47. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994, L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
48. Vagner, S., A. Waysbort, M. Marenda, M. C. Gensac, F. Amalric, and A. C. Prats. 1995. Alternative translation initiation of the Moloney murine leukemia virus mRNA controlled by internal ribosome entry involving the p57/PTB splicing factor. J. Biol. Chem. 270:20376-20383.
49. pro-binding peptides. J. Virol. 73:814-818.
50. Ventoso, I., A. Barco, and L. Carrasco. 1998. Mutational analysis of poliovirus 2Apro. Distinct inhibitory functions of 2Apro on translation and transcription. J. Biol. Chem. 273:27960-27967.
51. Ventoso, I., R. Blanco, C. Perales, and L. Carrasco, 2001. HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation. Proc. Natl. Acad. Sci. USA 98:12966-12971.
52. pro mutant unable to cleave 3CD shows inefficient viral protein synthesis and transactivation defects. J. Virol. 69:6280-6288.
53. Waskiewicz, A. J., A. Flynn, C. G. Proud, and J. A. Cooper. 1997. Mitogen-activated protein kinases activate the serine/threonine kinases Mnkl and Mnk2. EMBO J. 16:1909-1920.
54. Wells, S. E., P. E. Hillner, R. D. Vale, and A. B. Sachs. 1998. Circularization of mRNA by eukaryotic translation initiation factors. Mol. Cell 2:135-140.
55. Wlodawer, A., and A. Gustchina. 2000. Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta 1477:16-34.
56. Yeager, M., E. M. Wilson-Kubalek, S. G. Weiner, P. O. Brown, and A. Rein. 1998. Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechanisms. Proc. Natl. Acad. Sci. USA 95:7299-7304.
57. Zamora, M., W. E. Marissen, and R. E. Lloyd. 2002. Multiple eIF4GI-specific protease activities present in uninfected and poliovirus-infected cells. J. Virol. 76:165-177.